Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 18/20 | 0.69 |
| ▸ | CDK2 | P24941 | 18/20 | 0.69 |
| ▸ | CCNK | O75909 | 18/20 | 0.69 |
| ▸ | CDK12 | Q9NYV4 | 18/20 | 0.69 |
| ▸ | CCNT1 | O60563 | 15/20 | 0.69 |
| ▸ | CDK9 | P50750 | 15/20 | 0.69 |
| ▸ | CDK7 | P50613 | 13/20 | 0.69 |
| ▸ | CCNH | P51946 | 13/20 | 0.69 |
| ▸ | MNAT1 | P51948 | 11/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25598393 | 0.88 | CCNE1 (0.65) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL17150675 | 0.86 | CDK7 (0.71) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL17150448 | 0.86 | CCNK (0.73) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL19024488 | 0.86 | CCNE1 (0.65) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL17150717 | 0.84 | CCNE1 (0.60) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL30456603 | 0.83 | CCNK (0.69) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL17150422 | 0.82 | CDK7 (0.68) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL20416186 | 0.82 | CCNK (0.62) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL24839343 | 0.82 | CCNK (1.00) | CCNE1CDK2CCNKCDK12CCNT1 | |
| SCHEMBL29498427 | 0.82 | CCNK (1.00) | CCNE1CDK2CCNKCDK12CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CCNE1 51/4885CDK2 10/4885CCNK 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.